[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05459233":3,"trial-entities:NCT05459233":263,"trial-summary:NCT05459233":267},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":22,"study_type":23,"primary_purpose":24,"phases":25,"enrollment_info":27,"interventions":30,"primary_outcomes":40,"secondary_outcomes":49,"sex":96,"minimum_age":97,"maximum_age":98,"healthy_volunteers":15,"eligibility_criteria":99,"std_ages":111,"locations":114,"central_contacts":224,"overall_officials":228,"references":230,"see_also_links":262},"NCT05459233","ECHOCATH","Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR","Valve Hemodynamic Optimization Based on Doppler-Echocardiography Versus Catheterization Measurements Following Valve-in-Valve TAVR: A Prospective Randomized Trial","RECRUITING","2029-09-01","2026-03","2026-03-24","2023-01-11","Institut universitaire de cardiologie et de pneumologie de Québec, University Laval","OTHER",false,"Data on valve performance following ViV-TAVR has usually been obtained with the use of Doppler-echocardiography. However, some reports have shown significant discordances in the evaluation of mean transvalvular gradient between echocardiography and catheterization, with an overestimation of the real gradient with echo (vs. cath) in most cases. Thus, the incidence of procedural-device failure may be lower than that reported in the ViV-TAVR literature,","This is a prospective, multicenter, randomized, single-blinded design trial including patients with surgical aortic bioprosthetic dysfunction in the presence of a stented surgical bioprosthesis with a labeled size ≤25 mm. Following the Heart Team's decision to proceed with a ViV-TAVR procedure with the SAPIEN 3 ULTRA valve (or its subsequent iterations), patients will be randomized to valve hemodynamic optimization according to Doppler-echocardiography versus cardiac catheterization parameters.",[19,20,21],"Aortic Valve Stenosis","Aortic Valve Regurgitation","Prosthesis Failure",[],"INTERVENTIONAL","TREATMENT",[26],"NA",{"count":28,"type":29},310,"ESTIMATED",[31,36],{"type":32,"name":33,"description":34,"armGroupLabels":35},"PROCEDURE","Doppler-echocardiography","The TAVR (valve-in-valve) procedure will be performed with the SAPIEN 3 Ultra valve, with valve sizing according to current manufacturer recommendations. Following valve implantation, further intervention will be based on Doppler-echocardiographic measurements. Balloon post-dilation with a non-compliant balloon will be performed in the presence of a residual mean gradient ≥20 mmHg as assessed by Doppler-echocardiography.",[33],{"type":32,"name":37,"description":38,"armGroupLabels":39},"Invasive hemodynamic measurements","The TAVR (valve-in-valve) procedure will be performed with the SAPIEN 3 Ultra valve, with valve sizing according to current manufacturer recommendations. Following valve implantation, further interventions will be based on invasive hemodynamic measurements (with simultaneous aortic and ventricular pressure recording). Balloon post-dilation will be performed with a non-compliant balloon in the presence of a mean residual gradient ≥20 mmHg as assessed by hemodynamic measurements.",[37],[41,45],{"measure":42,"description":43,"timeFrame":44},"Changes in Quality of life (Efficacy)","Change in quality of life as evaluated by the Kansas City Cardiomyopathy Questionnaire (KCCQ). All score are represented on a 0-to-100-point scale (lower scores represent more severe symptoms and\u002For limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life).The KCCQ is a 7 domains questionnaire; symptom frequency, symptom burden, symptom stability, physical limitations, social limitations, quality of life and self-efficacy.","12 months follow-up",{"measure":46,"description":47,"timeFrame":48},"Periprocedural complications (Safety)","Periprocedural complications including in-hospital mortality, stroke, annular rupture, coronary obstruction, new-onset left bundle branch block, need for permanent pacemaker implantation and conversion to open heart surgery.","Periprocedural",[50,54,57,61,64,68,71,74,77,80,83,86,89,92],{"measure":51,"description":52,"timeFrame":53},"Residual transvalvular gradient","Residual (maximal and mean) transvalvular gradient","1 month and 12 months follow-up",{"measure":55,"description":56,"timeFrame":53},"Combined enpoint: Moderate or severe prothesis-patient mismatch and\u002For moderate or severe aortic regurgitation (valve performance)","Moderate or severe prothesis-patient mismatch (defines as an index aortic valve area 0.85-0.66 cm2\u002Fm2 (moderate), ≤0.65 cm2\u002Fm2 (severe) for patient with BMI ˂30km\u002Fm2 and 0.70-0.56 cm2\u002Fm2 (moderate), ≤0.55 cm2\u002Fm2 (severe) for patient with BMI ≥30km\u002Fm2 and\u002For moderate-severe aortic regurgitation (AR) (VARC-3 definition).",{"measure":58,"description":59,"timeFrame":60},"Heart failure","Evaluated by the New York Heart Association (NYHA) Functional Classification","1 and 12 months follow-up and yearly up to 5 years",{"measure":62,"description":63,"timeFrame":53},"Exercise capacity","Exercise capacity as evaluated by the six-minute wlak test.",{"measure":65,"description":66,"timeFrame":67},"Changes in Quality of life","severe symptoms and\u002For limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life).The KCCQ is a 7 domains questionnaire; symptom frequency, symptom burden, symptom stability, physical limitations, social limitations, quality of life and self-efficacy.","after 1-year follow-up (yearly up to 5 years)",{"measure":69,"description":70,"timeFrame":60},"Clinical safety endpoints","Individually and combined: death, stroke, major of lifethreatening bleeding, pacemaker implantation, myocardial infarction",{"measure":72,"description":73,"timeFrame":60},"re-hospitalization","Need for re-hospitalization",{"measure":75,"description":76,"timeFrame":60},"wear and tear deterioration (Structural valve degeneration)","wear and tear evaluated by echocardiography imaging",{"measure":78,"description":79,"timeFrame":60},"Leaflet disruption (Structural valve degeneration)","leaflet disruption evaluated by echocardiography imaging",{"measure":81,"description":82,"timeFrame":60},"flail leaflet (Structural valve degeneration)","flail leaflet evaluated by echocardiography imaging",{"measure":84,"description":85,"timeFrame":60},"leaflet fibrosis and\u002For calcification (Structural valve degeneration)","leaflet fibrosis and\u002For calcification evaluated by echocardiography imaging",{"measure":87,"description":88,"timeFrame":60},"strut fracture or deformation (Structural valve degeneration)","strut fracture or deformation evaluated by echocardiography imaging",{"measure":90,"description":91,"timeFrame":60},"Valve re-intervention","Need for valve re-intervention",{"measure":93,"description":94,"timeFrame":95},"Changes in Left ventricle mass","Changes in LV mass","1-month and 1-year follow-up","ALL","18 Years",null,{"inclusion":100,"exclusion":104,"raw_text":110},[101,102,103],"Patients with surgical aortic bioprosthetic valve failure defined as severe aortic stenosis and\u002For regurgitation approved for a valve-in-valve procedure by the Heart Team","Surgical stented bioprosthetic valve (label size ≤25 mm)","TAVR with the SAPIEN 3 Ultra valve",[105,106,107,108,109],"Stentless or sutureless surgical valves","Trifecta bioprosthesis","Hancock II bioprosthesis","High-risk of coronary obstruction (defined either as a virtual transcatheter valve - coronary distance as evaluated by CT \\\u003C4 mm or based on the criterion of the heart team responsible for the procedure).","Impossibility to obtain written informed consent","Inclusion Criteria:\n\n* Patients with surgical aortic bioprosthetic valve failure defined as severe aortic stenosis and\u002For regurgitation approved for a valve-in-valve procedure by the Heart Team\n* Surgical stented bioprosthetic valve (label size ≤25 mm)\n* TAVR with the SAPIEN 3 Ultra valve\n\nExclusion Criteria:\n\n* Stentless or sutureless surgical valves\n* Trifecta bioprosthesis\n* Hancock II bioprosthesis\n* High-risk of coronary obstruction (defined either as a virtual transcatheter valve - coronary distance as evaluated by CT \\\u003C4 mm or based on the criterion of the heart team responsible for the procedure).\n* Impossibility to obtain written informed consent",[112,113],"ADULT","OLDER_ADULT",[115,132,146,160,175,189,204],{"facility":116,"status":117,"city":118,"state":119,"zip":120,"country":121,"contacts":122,"geoPoint":129},"University of California","NOT_YET_RECRUITING","San Francisco","California","94143","United States",[123,126],{"name":124,"role":125},"Sammy Elmariah","CONTACT",{"name":127,"role":125,"email":128},"Mallika Saxena","Mallika.Saxena@ucsf.edu",{"lat":130,"lon":131},37.77493,-122.41942,{"facility":133,"status":8,"city":134,"state":135,"zip":136,"country":121,"contacts":137,"geoPoint":143},"South Broward Hospital Disctrict D\u002FB\u002FA Memorial Healthcare System","Hollywood","Florida","33021",[138,140],{"name":139,"role":125},"Houman Khalili",{"name":141,"role":125,"email":142},"Hina Khan","hikhan@mhs.net",{"lat":144,"lon":145},26.0112,-80.14949,{"facility":147,"status":8,"city":148,"state":149,"zip":150,"country":121,"contacts":151,"geoPoint":157},"William Beaumont Hospital","Royal Oak","Michigan","48073",[152,154],{"name":153,"role":125},"Amr Abbas",{"name":155,"role":125,"email":156},"Lauren Scribner","Lauren.Scribner@corewellhealth.org",{"lat":158,"lon":159},42.48948,-83.14465,{"facility":161,"status":8,"city":162,"state":163,"zip":164,"country":121,"contacts":165,"geoPoint":172},"Mayo Clinic","Rochester","Minnesota","55905",[166,168],{"name":167,"role":125},"Mackram F Eleid, M.D.",{"name":169,"role":125,"phone":170,"email":171},"Tricia A","(507) 422-3897","conley.tricia@mayo.edu",{"lat":173,"lon":174},44.02163,-92.4699,{"facility":176,"status":117,"city":177,"state":178,"zip":179,"country":121,"contacts":180,"geoPoint":186},"St-Joseph's Health INC","Syracuse","New York","13203",[181,183],{"name":182,"role":125},"Ayman Iskander",{"name":184,"role":125,"email":185},"Laura Mowers","laura.mowers@sjhcardiology.org",{"lat":187,"lon":188},43.04812,-76.14742,{"facility":190,"status":8,"city":191,"state":192,"zip":193,"country":121,"contacts":194,"geoPoint":201},"The Christ Hospital Health Network","Cincinnati","Ohio","45219",[195,197],{"name":196,"role":125},"Santiago Garcia, M.D.",{"name":198,"role":125,"phone":199,"email":200},"Susan Reilly","513-585-2165","Susan.Reilly@thechristhospital.com",{"lat":202,"lon":203},39.12711,-84.51439,{"facility":205,"status":8,"city":206,"state":207,"zip":208,"country":209,"contacts":210,"geoPoint":221},"IUCPQ","Québec","Quebec","G1V 4G5","Canada",[211,215,219],{"name":212,"role":125,"phone":213,"email":214},"Josep Rodes-Cabau, MD","418-656-8711","josep.rodes@criucpq.ulaval.ca",{"name":216,"role":125,"phone":213,"phoneExt":217,"email":218},"Emilie Pelletier Beaumont, MSc","3929","emilie.pelletier-beaumont@criucpq.ulaval.ca",{"name":212,"role":220},"PRINCIPAL_INVESTIGATOR",{"lat":222,"lon":223},46.81228,-71.21454,[225,227],{"name":226,"role":125,"phone":213,"email":214},"Josep Rodés-Cabau, MD",{"name":216,"role":125,"phone":213,"phoneExt":217,"email":218},[229],{"name":226,"affiliation":13,"role":220},[231,235,238,241,244,247,250,253,256,259],{"pmid":232,"type":233,"citation":234},"26516006","BACKGROUND","Paradis JM, Del Trigo M, Puri R, Rodes-Cabau J. Transcatheter Valve-in-Valve and Valve-in-Ring for Treating Aortic and Mitral Surgical Prosthetic Dysfunction. J Am Coll Cardiol. 2015 Nov 3;66(18):2019-2037. doi: 10.1016\u002Fj.jacc.2015.09.015.",{"pmid":236,"type":233,"citation":237},"33888385","VARC-3 WRITING COMMITTEE:; Genereux P, Piazza N, Alu MC, Nazif T, Hahn RT, Pibarot P, Bax JJ, Leipsic JA, Blanke P, Blackstone EH, Finn MT, Kapadia S, Linke A, Mack MJ, Makkar R, Mehran R, Popma JJ, Reardon M, Rodes-Cabau J, Van Mieghem NM, Webb JG, Cohen DJ, Leon MB. Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research. J Am Coll Cardiol. 2021 Jun 1;77(21):2717-2746. doi: 10.1016\u002Fj.jacc.2021.02.038. Epub 2021 Apr 19.",{"pmid":239,"type":233,"citation":240},"25005653","Dvir D, Webb JG, Bleiziffer S, Pasic M, Waksman R, Kodali S, Barbanti M, Latib A, Schaefer U, Rodes-Cabau J, Treede H, Piazza N, Hildick-Smith D, Himbert D, Walther T, Hengstenberg C, Nissen H, Bekeredjian R, Presbitero P, Ferrari E, Segev A, de Weger A, Windecker S, Moat NE, Napodano M, Wilbring M, Cerillo AG, Brecker S, Tchetche D, Lefevre T, De Marco F, Fiorina C, Petronio AS, Teles RC, Testa L, Laborde JC, Leon MB, Kornowski R; Valve-in-Valve International Data Registry Investigators. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA. 2014 Jul;312(2):162-70. doi: 10.1001\u002Fjama.2014.7246.",{"pmid":242,"type":233,"citation":243},"32592401","Bleiziffer S, Simonato M, Webb JG, Rodes-Cabau J, Pibarot P, Kornowski R, Windecker S, Erlebach M, Duncan A, Seiffert M, Unbehaun A, Frerker C, Conzelmann L, Wijeysundera H, Kim WK, Montorfano M, Latib A, Tchetche D, Allali A, Abdel-Wahab M, Orvin K, Stortecky S, Nissen H, Holzamer A, Urena M, Testa L, Agrifoglio M, Whisenant B, Sathananthan J, Napodano M, Landi A, Fiorina C, Zittermann A, Veulemans V, Sinning JM, Saia F, Brecker S, Presbitero P, De Backer O, Sondergaard L, Bruschi G, Franco LN, Petronio AS, Barbanti M, Cerillo A, Spargias K, Schofer J, Cohen M, Munoz-Garcia A, Finkelstein A, Adam M, Serra V, Teles RC, Champagnac D, Iadanza A, Chodor P, Eggebrecht H, Welsh R, Caixeta A, Salizzoni S, Dager A, Auffret V, Cheema A, Ubben T, Ancona M, Rudolph T, Gummert J, Tseng E, Noble S, Bunc M, Roberts D, Kass M, Gupta A, Leon MB, Dvir D. Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves. Eur Heart J. 2020 Aug 1;41(29):2731-2742. doi: 10.1093\u002Feurheartj\u002Fehaa544.",{"pmid":245,"type":233,"citation":246},"30354588","de Freitas Campos Guimaraes L, Urena M, Wijeysundera HC, Munoz-Garcia A, Serra V, Benitez LM, Auffret V, Cheema AN, Amat-Santos IJ, Fisher Q, Himbert D, Garcia Del Blanco B, Dager A, Le Breton H, Paradis JM, Dumont E, Pibarot P, Rodes-Cabau J. Long-Term Outcomes After Transcatheter Aortic Valve-in-Valve Replacement. Circ Cardiovasc Interv. 2018 Sep;11(9):e007038. doi: 10.1161\u002FCIRCINTERVENTIONS.118.007038.",{"pmid":248,"type":233,"citation":249},"30003366","Wernly B, Zappe AK, Unbehaun A, Sinning JM, Jung C, Kim WK, Fichtlscherer S, Lichtenauer M, Hoppe UC, Alushi B, Beckhoff F, Wewetzer C, Franz M, Kretzschmar D, Navarese E, Landmesser U, Falk V, Lauten A. Transcatheter valve-in-valve implantation (VinV-TAVR) for failed surgical aortic bioprosthetic valves. Clin Res Cardiol. 2019 Jan;108(1):83-92. doi: 10.1007\u002Fs00392-018-1326-z. Epub 2018 Jul 12.",{"pmid":251,"type":233,"citation":252},"31146808","Webb JG, Murdoch DJ, Alu MC, Cheung A, Crowley A, Dvir D, Herrmann HC, Kodali SK, Leipsic J, Miller DC, Pibarot P, Suri RM, Wood D, Leon MB, Mack MJ. 3-Year Outcomes After Valve-in-Valve Transcatheter Aortic Valve Replacement for Degenerated Bioprostheses: The PARTNER 2 Registry. J Am Coll Cardiol. 2019 Jun 4;73(21):2647-2655. doi: 10.1016\u002Fj.jacc.2019.03.483.",{"pmid":254,"type":233,"citation":255},"34003666","Kaneko T, Makkar RR, Krishnaswami A, Hermiller J, Greenbaum A, Babaliaros V, Shah PB, Bailey SH, Bapat V, Kapadia S, Abbas AE. Valve-in-Surgical-Valve With SAPIEN 3 for Transcatheter Aortic Valve Replacement Based on Society of Thoracic Surgeons Predicted Risk of Mortality. Circ Cardiovasc Interv. 2021 May;14(5):e010288. doi: 10.1161\u002FCIRCINTERVENTIONS.120.010288. Epub 2021 May 18.",{"pmid":257,"type":233,"citation":258},"29593832","Saxon JT, Allen KB, Cohen DJ, Chhatriwalla AK. Bioprosthetic Valve Fracture During Valve-in-valve TAVR: Bench to Bedside. Interv Cardiol. 2018 Jan;13(1):20-26. doi: 10.15420\u002Ficr.2017:29:1.",{"pmid":260,"type":233,"citation":261},"31867060","O'Donnell JP, O'Sullivan CJ. Bioprosthetic Aortic Valve Fracture During Valve-in-valve Transcatheter Aortic Valve Implantation. Interv Cardiol. 2019 Nov 18;14(3):147-151. doi: 10.15420\u002Ficr.2019.08.R2. eCollection 2019 Nov.",[],{"nct_id":4,"conditions":264,"biomarkers":266},[265,19,21],"Aortic Valve Insufficiency",[],{"nct_id":4,"found":268,"summary":269,"prompt_version":279},true,{"design":270,"status":271,"heading":272,"summary":273,"follow_up":274,"word_count":275,"commitments":276,"compensation":277,"drugs_mentioned":278},"This is a prospective, multicenter, randomized, single-blinded study. It will include 310 participants.","completed","Valve Optimization for ViV TAVR","This study is looking at the best way to optimize a new heart valve after a procedure called valve-in-valve Transcatheter Aortic Valve Replacement (ViV TAVR). ViV TAVR is when a new valve is placed inside an old, failing surgical heart valve. Researchers are comparing two methods to guide this optimization: using Doppler-echocardiography (a type of ultrasound) or using invasive hemodynamic measurements (measurements taken directly inside the heart with a catheter). You may be able to join if you have a failing surgical aortic valve (Aortic Valve Stenosis or Aortic Valve Regurgitation) that is approved for a ViV TAVR with the SAPIEN 3 Ultra valve. The study aims to see how these different optimization methods affect your quality of life and any complications during the procedure. The study plans to enroll 310 participants.","Your quality of life will be measured at 12 months after the procedure, and periprocedural complications will be measured around the time of the procedure.",132,"You would undergo a ViV TAVR procedure with the SAPIEN 3 Ultra valve, with further interventions based on either Doppler-echocardiography or invasive hemodynamic measurements.","Not stated in the trial record.",[33,37],"v2"]